Serum amyloid A3, pseudogene (SAA3P)

Serum amyloid A3, pseudogene, refers to the human ortholog (SAA3P) of mouse SAA3, a member of the serum amyloid A (SAA) gene family. In humans, SAA3 contains a frame-shift in exon 2 due to a unique oligonucleotide insertion, resulting in a short pseudo open reading frame and disruption of standard protein production[1]. For decades, it was considered a non-coding pseudogene with no expected protein output[1][4]. However, recent evidence suggests that SAA3 sequences can be transcribed as part of rare SAA2-SAA3 fusion transcripts, generating truncated or fusion proteins detectable in certain cell lines[1]. Some studies detected translation of the fusion protein and weak evidence for biological activity, including binding to the LOX-1 (oxidized LDL receptor) and activation of MAP kinase signaling in vitro, though any physiological or disease relevance in humans remains uncertain[1]. In mice, SAA3 is a functional extrahepatic acute-phase protein involved in inflammation and immune responses. The human SAA3 pseudogene is fundamentally different in that it does not produce a stand-alone full-length protein, and is not currently regarded as a therapeutic target or biomarker of disease[4]. Serum amyloid A3, pseudogene (SAA3P), is a non-functional human gene orthologous to mouse SAA3. It is not a therapeutic target, does not produce a conventional protein, and has no established biological or disease roles in humans[1][2][4]. Any experimental fusion-transcript functions are still unproven for physiological or clinical relevance.

Other names

SAA3PSAA3